Community-onset bacteremia due to extended-spectrum β-lactamase- producing Escherichia coli: Risk factors and prognosis

Clinical Infectious Diseases

Volumn 50, Issue 1, 2010, Pages 40-48

  Rodríguez Baño, Jesús ^a   Picón, Encarnación ^a   Gijón, Paloma ^c   Hernández, José Ramón ^a   Ruíz, Maite ^b   Peña, Carmen ^e   Almela, Manuel ^f   Almirante, Benito ^g   Grill, Fabio ^d,n   Colomina, Javier ⁱ   Giménez, Monserrat ^j   Oliver, Antonio ^k   Horcajada, Juan Pablo ^l,o   Navarro, Gemma ^m   Coloma, Ana ^h   Pascual, Alvaro ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

ⁱ Hospital Universitario de la Ribera   (Spain)

^j HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^k HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^l HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^m Servicio de Oncología Médica   (Spain)

ⁿ HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^o HOSPITAL DEL MAR   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; EXTENDED SPECTRUM BETA LACTAMASE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AGED; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; CLINICAL FEATURE; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; URINARY CATHETER;

EID: 72049128093     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/649537     Document Type: Article

References (36)

1. Wisplinghoff H, Bischoff T, Talent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide study. Clin Infect Dis 2004; 39:309-317. (Pubitemid 39050477)
2. Friedman ND, Kaye KS, Stout JE, et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definitions of community-acquired bacteremia. Ann Intern Med 2002; 137:791-797.
3. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis 1999; 29:745-758. (Pubitemid 30256361)
4. Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37:997-1005.
5. Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004; 39:885-910. (Pubitemid 39328144)
6. Peralta G, Sánchez MB, Garrido JC, et al. Impact of antibiotic resistance and adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. J Antimicrob Chemother 2007; 60: 855-863.
7. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005; 18:657-686.
8. Paterson DL, Ko WC, Von Gottberg A, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum β-lactamase production in nosocomial infections. Ann Intern Med 2004; 140:26-32.
9. Pitout JDD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005; 56:52-59. (Pubitemid 41418336)
10. Rodríguez-Baño J, Alcalá J, Cisneros JM, et al. Community infections caused by extended-spectrum ß-lactamase-producing Escherichia coli. Arch Intern Med 2008; 168:1807-1902.
11. Rodríguez-Baño J, Navarro MD, Romero L, et al. Bacteremia due to extended-spectrum -lactamase-producing Escherichia coli in the CTXM era: a new clinical challenge. Clin Infect Dis 2006; 43:1407-1414.
12. Kang CI, Cheong HS, Chung DR, et al. Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Eur J Clin Microbiol Infect Dis 2008; 27:85-88.
13. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008; 61:344-349. (Pubitemid 351289042)
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic co-morbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40:373-383. (Pubitemid 17055592)
15. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee: definitions for sepsis and organ failure and guidelines for use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874.
16. CLSI. Performance standards for antimicrobial susceptibility testing: 15th informational supplement. CLSI document M100-S15. Wayne, PA: CLSI, 2005.
17. Hernández JR, Martínez-Martínez L, Cantón R, Coque MT, Pascual A; Spanish Group for Nosocomial Infections (GEIH). Nationwide study of Escherichia coli and Klebsiella pneumoniae producing extended-spectrum ß-lactamases in Spain. Antimicrob Agents Chemother 2005; 49:2122-2125.
18. Vila J, Marcos MA, Jiménez de Anta MT. A comparative study of different PCR-based DNA fingerprinting techniques for typing of the Acinetobacter calcoaceticus-A. baumannii complex. J Med Microbiol 1996; 44:482-489.
19. Barret TJ, Lior H, Green JH, et al. Laboratory investigation of a multistate food-borne outbreak of Escherichia coli O157:H7 by using pulsed-field gel electrophoresis and phage typing. J Clin Microbiol 1994; 33:3013-3017.
20. Romero L, López L, Rodríguez-Baño J, Hernández JR, Martínez-Martínez L, Pascual A. Long-term study of the frequency of ESBL-producing Escherichia coli and Klebsiella pneumoniae isolates. Clin Microbiol Infect 2005; 11:625-631.
21. Diestra K, Coque TM, Miró E, et al. Caracterización y epidemiología molecular de betalactamasas de espectro extendido en Escherichia coli y Klebsiella pneumoniae en 11 hospitales españoles (2004). Enferm Infecc Microbiol Clin 2008; 26:404-410.
22. Ho PL, Chan WM, Tsang KWT, Wong SSY, Yuong K. Bacteremia caused by Escherichia coli producing extended-spectrum β-lactamase: a casecontrol study of risk factors and outcomes. Scand J Infect Dis 2002; 34:567-573.
23. Metan G, Zarakolu P, Cakir B, Hascelik C, Uzun O. Clinical outcomes and therapeutic options of bloodstream infections caused by extende-dspectrum β-lactamase-producing Escherichia coli. Int J Antimicrob Agents 2005; 26:254-257. (Pubitemid 41219613)
24. Bin C, Hui W, Renyuan Z, et al. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli. Diagn Microbiol Infect Dis 2006; 56:351-357.
25. Melzer M, Petersen I. Mortality following bacteraemic infection caused by extended spectrum β-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Infect 2007; 55: 254-259 (Pubitemid 47244918)
26. Harris AD, Karchmer TB, Carmeli Y, Samore SH. Methodological principles of case-control studies that analysed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis 2001; 32:1055-1061. (Pubitemid 32299641)
27. Kaye KS, Harris AD, Samore M, Carmeli Y. The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect Control Hosp Epidemiol 2005; 26:346-351. (Pubitemid 40545579)
28. Rodríguez-Baño J, Navarro MD, Romero L, et al. Risk-factors for emerging bloodstream infections caused by extended-spectrum βlactamase-producing Escherichia coli. Clin Microbiol Infect 2008; 14:180-183.
29. Rodríguez-Baño J, Navarro MD, Romero L, et al. Clinical and molecular epidemiology of extended-spectrum β-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. Clin Infect Dis 2006; 42:37-45.
30. Valverde A, Coque TM, Sánchez-Moreno MP, Rollán A, Baquero F, Cantón R. Dramatic increase in prevalence of fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol 2004; 42:4769-4775. (Pubitemid 39362401)
31. Rodríguez-Baño J, Ló pez-Cerero L, Navarro MD, Díaz de Alba P, Pascual A. Faecal carriage of extended-spectrum β-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology. J Antimicrob Chemother 2008; 62:1142-1149.
32. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003; 115:529-535. (Pubitemid 37352798)
33. MacGowan A. Breakpoints for extended-spectrum β-lactamase-producing Enterobacteriacae: pharmacokinetic/pharmacodynamic considerations. Clin Microbiol Infect 2008; 14(Suppl 1):166-168.
34. Livermore DM, Hawkey PM. CTX-M: changing the face of ESBLs in the UK. J Antimicrob Chemother 2005; 56:451-454.
35. Vasilev K, Reshedko G, Orasan R, et al. A phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother 2008; 62(Suppl 1):i29-i40.
36. Coque TM, Novais A, Carattoli A, et al. Dissemination of clonally related Escherichia coli strains expressing extended-spectrum β-lactamase CTX-M-15. Emerg Infect Dis 2008; 14:195-200.